NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ketorolac for Pain Management: A Review of the Clinical Evidence [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jun 30.

APPENDIX 4Main Study Findings

Tables

Table 1Main Findings from Jena et al., 20136

Treatment
Ketorolac
(n=20)
Ibuprofen
(n=20)
Etodolac +
Paracetamol
(n=20)
Aceclofenac
(n=20)
Placebo
(n=20)
Pain before local anesthesia- Heft-Parker VAS score (mm)
Mean (SD)128.00 (20.17)122.05 (17.19)125.05 (22.59)125.30 (25.57)119.05 (15.76)
Pain during endodontic treatment- Heft-Parker VAS score (mm)
Mean (SD)27.80 (47.02)46.30 (54.23)46.50 (51.10)39.85 (52.02)62.35 (55.37)
Level of pain - Heft-Parker VAS score, n(%)
No Pain
(0mm)
14(70)1(55)10(50)11(55)8(40)
Mild
(1mm to 54mm)
2(10)01(5)3(15)0
Moderate
(55mm to 85mm)
03(15)4(20)1(5)3(15)
Severe
(86mm to 170mm)
4(20)6(30)5(25)5(25)9(45)

VAS = visual analogue scale

a

Heft-Parker VAS scale ranging from 1 to 170 mm, where 0mm = no pain, 1mm to 54mm = mild pain, 54 mm to 114mm = moderate pain, and > 114mm = severe pain

Table 2Main Findings from Aggarwal et al., 20107

Treatment
Ketorolac
(n=23)
Ibuprofen
(n=22)
Placebo
(n=24)
Mild Pain (Heft-Parker VAS score < 54 mm) during endodontic treatment
n (%)9 (39)6 (27)7 (29)
Moderate Pain (Heft-Parker VAS score 54mm to 114mm) during endodontic treatment
Within dentin
n/N (%)
4/14 (29)4/16 (25)5/17 (29)
Within pulpal space
n/N (%)
3/14 (21)2/16 (13)2/17 (12)
Instrumentation of canals
n/N (%)
2/14 (14)2/16 (13)2/17 (12)
Severe Pain (Heft-Parker VAS score > 114 mm) during endodontic treatment
Within dentin
n/N (%)
3/14 (21)5/16 (31)3/17 (18)
Within pulpal space
n/N (%)
1/14 (7)3/16 (19)4/17 (24)
Instrumentation of canals
n/N (%)
1/14 (7)2/16 (13)1/17 (6)

VAS = visual analogue scale

a

Heft-Parker VAS scale ranging from 1 to 170 mm, where 0mm = no pain, 1mm to 54mm = mild pain, 54 mm to 114mm = moderate pain, and > 114mm = severe pain

Table 3Main Findings from Ortiz et al. 20108

Treatment
Ketorolac
(n=15)
Etoricoxib
(n=17)
Diclofenac
(n=17)
Pain at 24h post-treatment (VAS mm)a
Mean (SE)21.2 (4.3)20.1 (4.5)21.9 (5)
Pain at 24h post-treatment (Likert Scale)b
Mean (SE)1.13 (0.8)1.13 (0.9)1.07 (0.7)

SE = standard error; VAS = visual analogue scale

a

visual analogue scale ranged from 0 (no pain) to 10 (worst pain)

b

1 represents slight relief, pain intermittently throughout the study; 2 represents moderate relief, pain intermittently throughout the study, and 3 represents no pain subsided with treatment

Table 4Main Findings from Kaeding et al. 20049

Treatment
Ketorolac
(n=25)
Rofecoxib
(n=25)
Pain 5 days post-operation (VAS)a
Mean (SD)3.49 (NR)3.57 (NR)
Mean change from baseline (SD)−0.24 (NR)0.13 (NR)
Overall Daily Pain (VAS)a
Mean (SD)3.76 (NR)4.09 (NR)
Adverse Events
Incision-site bleeding, n (%)7 (28)2 (8)
Nausea, n (%)4 (16)7 (28)

NR = not reported; SD = standard deviation; VAS = visual analogue scale

a

visual analogue scale ranging from 1 representing great pain to 5 representing no pain

Copyright © 2014 Canadian Agency for Drugs and Technologies in Health.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK254114